| abstract |
The present disclosure is mainly a pharmaceutical composition and a method for manufacturing a pharmaceutical composition for treating a disease (eg, cancer). Here, the pharmaceutical composition refers to a recombinant chimeric antigen receptor. More specifically, the pharmaceutical composition comprises: a recombinant chimeric antigen receptor protein with high specificity for CD19, a vector capable of inducing cells to produce the recombinant chimeric antigen receptor protein, and a group of improved mammalian cells comprising at least one of the foregoing Protein, carrier, or both. In addition, the recombinant chimeric antigen receptor 19 includes a CD19 antigen-binding fragment, a transmembrane region, and a message region. The CD19 antigen-binding fragment is a single-chain variable region fragment having a specific amino acid sequence. In another example, the manufacturing method is to produce a population of improved mammalian cells to treat a disease. In addition, the method for manufacturing an improved cell for treating a disease comprises purifying a population of auto-derived cells and modifying the auto-derived cells with a recombinant chimeric antigen receptor. |